Pipeline

Live Biotherapeutics for Patients with Metabolic and Neurological Disorders

Bloom’s robust clinical and discovery programs aim to address unmet medical needs for metabolic health and devastating neurological diseases. Bloom’s programs and research areas include obesity, metabolic disorders, Dravet syndrome, Developmental and Epileptic Encephalopathies (DEEs), Amyotrophic Lateral Sclerosis (ALS), and neurodegenerative and cognitive disorders.

Discovery Programs

We have two areas of focus in our Discovery programs.

Our first area of focus is on designing consortia of commensal bacterial strains found in the mucosal layer of the gut. This is enabling us to screen and develop breakthrough therapies with superior efficacy and safety profiles for multiple diseases, including metabolic disorders and neurodegenerative diseases such as Alzheimer disease.

The next frontier in the field of microbiome therapeutics is the development of genetically-engineered bacterial strains via synthetic biology tools. This area of focus involves us using our toolkit to enhance the natural abilities of bacteria or insert useful functions into bacteria to tackle specific disease indications.